Exicure (XCUR) FCF Margin (2016 - 2024)

Exicure's (XCUR) quarterly FCF Margin came in at 90.0% in Q1 2024, down 169.33% on a QoQ basis from 33.42% in Q4 2022.

Exicure (XCUR) FCF Margin (2016 - 2024) Analysis & Trends

Exicure (XCUR) has 8 years of FCF Margin data on file, last reported at 90.0% in Q1 2024.

Quarterly FCF Margin changed N/A year-over-year to 90.0% in Q1 2024, while the trailing twelve-month figure through Dec 2024 was 582.0% (changed N/A YoY) and the FY2024 annual result came in at 582.0%, changed N/A from the prior year.
FCF Margin eased to 90.0% in Q1 2024, from 33.42% in the prior quarter.
In the past five years, FCF Margin ranged from a high of 637.54% in Q4 2021 to a low of 14012.66% in Q2 2021.
A 4-year average of 1941.44% and a median of 312.24% in 2020 frame the typical range for FCF Margin.
Annual changes were most pronounced in 2020 — FCF Margin soared 1599488 bps — and 2021, when it tumbled 1376444 bps.
Tracing XCUR's FCF Margin over 4 years: stood at 8539.29% in 2020, then soared by 107 bps to 637.54% in 2021, then sank by 105 bps to 33.42% in 2022, then slumped by 169 bps to 90.0% in 2024.
The last three FCF Margin figures came in at 90.0% (Q1 2024), 33.42% (Q4 2022), and 326.49% (Q3 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	13.35%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	22.62%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-22.35%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	70.82%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	41.07%
10	Exicure	8.41 Mn	8.41 Mn	-	-

Download Data